Additional Acquisitions: #Visma > #WeFact; #WorkWise > #Bizhaven

Agreed Acquisitions: #Asurion > #Domestic&General; #Hims&HersHealth > #YourBioHealth; #IBM > #Confluent; #MirumPharmaceuticals > #BluejayTherapeutics; #L’Oreal > #GaldermaGroup

IPO: #LumexaImaging raised $462.5M

Mirum Begins Phase 2 Trial of MRM-3379 in Fragile X Syndrome Mirum Pharmaceuticals (NASDAQ: MIRM) has enrolled the first patient in its BLOOM Phase 2 study evaluating MRM-3379 for Fragile X syndrome (FXS), marking a meani

(NASDAQ: #MIRM)
#MirumPharmaceuticals has begun the Phase 2 BLOOM trial of MRM-3379, an oral PDE4D inhibitor, in males with Fragile X syndrome, aiming to improve cognition, behavior, and daily function where no approved therapies currently exist. The 12-week study
prismmarketview.com/mirum-begins...